Eleva Enters Clinical Development of Difficult-To-Express High...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire-AsiaNet/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produ...
Authors: LATEST ASIANET NEWS RELEASES